PTPN11 and myeloid sarcoma: SHP-2 may also participate in T cell driven pathology in MS, as treatment of mice with a SHP-2 inhibitor enabled resistance to induction of EAE following inoculation with myelin oligodendrocyte glycoprotein35-55 (MOG) protein, via prevention of infiltration of CD8 T cells into the CNS (Luo et al., 2014).